BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BC Extra | Jan 16, 2019
Tools & Techniques

Researchers develop AI tool to improve screening for cervical cancer

A team from NCI and Intellectual Ventures Global Good Fund released a paper Thursday detailing an image-based, machine-learning algorithm that improves screening accuracy for precancerous cervical lesions. The tool could help reduce the incidence of...
BC Week In Review | May 25, 2018
Clinical News

Dendreon takes Provenge earlier in prostate cancer

Dendreon Pharmaceuticals LLC announced it will study Provenge sipuleucel-T to prevent progression in men undergoing active surveillance for prostate cancer. Provenge comprises autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and...
BC Extra | May 18, 2018
Clinical News

Dendreon takes Provenge earlier in prostate cancer

Dendreon Pharmaceuticals LLC announced it will study Provenge sipuleucel-T to prevent progression in men undergoing active surveillance for prostate cancer. Provenge comprises autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and...
BC Innovations | Apr 17, 2018
Distillery Techniques

Assays and screens

TECHNOLOGY: Diagnostic assays A method for detecting aneuploidy and mutations in 18 genes in Pap test or intrauterine fluids could help diagnose ovarian and endometrial cancers. The method involves using multiplexed PCR-based template preparation of...
BioCentury | Mar 10, 2018
Product Development

Defining progress

Erleada apalutamide’s landmark approval established a new primary endpoint in prostate cancer that shortens the time it takes to run the trials by up to five years, and paves the way for treating disease before...
BC Week In Review | Jan 5, 2018
Clinical News

OncBioMune reports additional Phase I data for prostate cancer vaccine

OncBioMune Pharmaceuticals Inc. (OTCQB:OBMP) reported additional data from 14 evaluable patients with hormone-naïve and hormone-independent recurrent prostate cancer with increasing prostate-specific antigen (PSA; KLK3) levels in a Phase I trial showing that six intradermal injections...
BioCentury | Sep 7, 2017
Strategy

What if you build, but they don’t come

Vaccination is widely considered one of the greatest medical achievements of modern civilization. Diseases that were commonplace less than a generation ago, such as polio, smallpox and diphtheria, are now increasingly rare because of vaccines....
BC Week In Review | Jul 6, 2017
Company News

Sanpower completes acquisition of Dendreon from Valeant

Sanpower Group Co. Ltd. (Nanjing, China) completed the purchase of Dendreon Pharmaceuticals Inc. from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) for $819.9 million in cash. In February 2015, Valeant acquired bankrupt Dendreon's assets, including global...
BC Extra | Jun 30, 2017
Company News

Sanpower completes Dendreon acquisition

Sanpower Group Co. Ltd. (Nanjing, China) said it completed the purchase of Dendreon Pharmaceuticals Inc. from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) for $819.9 million in cash. In February 2015, Valeant acquired bankrupt Dendreon's assets,...
Items per page:
1 - 10 of 242